U.S. Physical Therapy Toekomstige groei

Future criteriumcontroles 3/6

U.S. Physical Therapy zal naar verwachting groeien in winst en omzet met respectievelijk 29.4% en 8.9% per jaar. De winst per aandeel zal naar verwachting groeien met 40.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 9.2% zijn.

Belangrijke informatie

29.4%

Groei van de winst

40.1%

Groei van de winst per aandeel

Healthcare winstgroei	20.9%
Inkomstengroei	8.9%
Toekomstig rendement op eigen vermogen	9.2%
Dekking van analisten	Good
Laatst bijgewerkt	21 Nov 2024

Recente toekomstige groei-updates

Recent updates

Shareholders Should Be Pleased With U.S. Physical Therapy, Inc.'s (NYSE:USPH) Price

Nov 09

U.S. Physical Therapy (NYSE:USPH) Might Be Having Difficulty Using Its Capital Effectively

Aug 07

U.S. Physical Therapy (NYSE:USPH) Has A Rock Solid Balance Sheet

Jul 17

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Business Is Trailing The Industry But Its Shares Aren't

Jun 04

There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings

May 21

U.S. Physical Therapy (NYSE:USPH) Is Due To Pay A Dividend Of $0.44

May 11

Returns On Capital Signal Tricky Times Ahead For U.S. Physical Therapy (NYSE:USPH)

May 05

A Look At The Fair Value Of U.S. Physical Therapy, Inc. (NYSE:USPH)

Apr 21

Is Now The Time To Look At Buying U.S. Physical Therapy, Inc. (NYSE:USPH)?

Apr 07

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Shareholders Might Be Looking For Exit

Mar 04

The Returns On Capital At U.S. Physical Therapy (NYSE:USPH) Don't Inspire Confidence

Dec 23

Why U.S. Physical Therapy, Inc. (NYSE:USPH) Could Be Worth Watching

Dec 07

U.S. Physical Therapy: Positioned For Market Dominance Amidst Attractive Valuations

Oct 13

Are U.S. Physical Therapy, Inc. (NYSE:USPH) Investors Paying Above The Intrinsic Value?

Aug 01

U.S. Physical Therapy: Bolt-On Strategy Scaling Earnings Power (Rating Upgrade)

Jul 19

At US$114, Is U.S. Physical Therapy, Inc. (NYSE:USPH) Worth Looking At Closely?

May 07

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Intrinsic Value Is Potentially 25% Below Its Share Price

Apr 16

U.S. Physical Therapy (NYSE:USPH) Has A Pretty Healthy Balance Sheet

Apr 01

Some Investors May Be Worried About U.S. Physical Therapy's (NYSE:USPH) Returns On Capital

Mar 04

U.S. Physical Therapy beats Q4 top and bottom line estimates; initiates FY23 outlook

Feb 23

U.S. Physical Therapy: Needs To Illustrate Economic Reality Over Accounting Profit

Feb 12

Is Now An Opportune Moment To Examine U.S. Physical Therapy, Inc. (NYSE:USPH)?

Jan 24

We Think U.S. Physical Therapy (NYSE:USPH) Can Stay On Top Of Its Debt

Dec 20

Here's Why We Think U.S. Physical Therapy (NYSE:USPH) Is Well Worth Watching

Dec 05

U.S. Physical Therapy: Not The Most Comfortable Prospect

Nov 09

Winst- en omzetgroeiprognoses

NYSE:USPH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	778	48	83	87	3
12/31/2025	726	61	70	85	6
12/31/2024	662	50	65	81	6
9/30/2024	639	14	73	82	N/A
6/30/2024	621	16	68	77	N/A
3/31/2024	606	18	66	75	N/A
12/31/2023	599	18	73	82	N/A
9/30/2023	585	24	64	72	N/A
6/30/2023	575	26	62	70	N/A
3/31/2023	564	28	50	58	N/A
12/31/2022	548	29	50	59	N/A
9/30/2022	536	39	48	57	N/A
6/30/2022	522	38	59	68	N/A
3/31/2022	509	37	61	70	N/A
12/31/2021	490	31	68	76	N/A
9/30/2021	477	31	78	86	N/A
6/30/2021	461	30	81	87	N/A
3/31/2021	418	32	95	101	N/A
12/31/2020	418	32	92	100	N/A
9/30/2020	423	30	82	91	N/A
6/30/2020	431	31	72	82	N/A
3/31/2020	473	29	55	65	N/A
12/31/2019	477	31	52	62	N/A
9/30/2019	472	30	56	65	N/A
6/30/2019	468	23	62	71	N/A
3/31/2019	457	18	63	71	N/A
12/31/2018	449	17	66	73	N/A
9/30/2018	442	18	63	70	N/A
6/30/2018	432	22	N/A	65	N/A
3/31/2018	421	21	N/A	58	N/A
12/31/2017	410	22	N/A	57	N/A
9/30/2017	392	20	N/A	53	N/A
6/30/2017	377	20	N/A	42	N/A
3/31/2017	363	21	N/A	51	N/A
12/31/2016	353	21	N/A	51	N/A
9/30/2016	348	20	N/A	48	N/A
6/30/2016	344	21	N/A	49	N/A
3/31/2016	337	21	N/A	49	N/A
12/31/2015	327	21	N/A	38	N/A
9/30/2015	320	21	N/A	45	N/A
6/30/2015	313	20	N/A	43	N/A
3/31/2015	308	20	N/A	45	N/A
12/31/2014	301	19	N/A	41	N/A
9/30/2014	290	19	N/A	45	N/A
6/30/2014	278	18	N/A	45	N/A
3/31/2014	267	18	N/A	44	N/A
12/31/2013	260	18	N/A	45	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei USPH ( 29.4% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van USPH ( 29.4% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van USPH zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van USPH ( 8.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van USPH ( 8.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen USPH zal naar verwachting over 3 jaar laag zijn ( 9.2 %).

U.S. Physical Therapy Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 9.0% to US$119

Price target decreased by 9.6% to US$110

Consensus EPS estimates fall by 10%

Price target decreased by 7.9% to US$118

Price target increased by 7.9% to US$119

Price target increased by 7.5% to US$110

Recent updates

New minor risk - Insider selling

President & COO recently sold US$192k worth of stock

Shareholders Should Be Pleased With U.S. Physical Therapy, Inc.'s (NYSE:USPH) Price

Upcoming dividend of US$0.44 per share

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 6, 2024

U.S. Physical Therapy, Inc. to Report Q3, 2024 Results on Nov 05, 2024

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 13, 2024

U.S. Physical Therapy, Inc. announced delayed 10-Q filing

U.S. Physical Therapy (NYSE:USPH) Might Be Having Difficulty Using Its Capital Effectively

U.S. Physical Therapy, Inc. to Report Q2, 2024 Results on Aug 13, 2024

U.S. Physical Therapy (NYSE:USPH) Has A Rock Solid Balance Sheet

Now 20% undervalued after recent price drop

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Business Is Trailing The Industry But Its Shares Aren't

Chairman & CEO notifies of intention to sell stock

Chairman & CEO recently sold US$212k worth of stock

There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings

Chief Operating Officer - East recently sold US$261k worth of stock

U.S. Physical Therapy (NYSE:USPH) Is Due To Pay A Dividend Of $0.44

First quarter dividend of US$0.44 announced

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Returns On Capital Signal Tricky Times Ahead For U.S. Physical Therapy (NYSE:USPH)

A Look At The Fair Value Of U.S. Physical Therapy, Inc. (NYSE:USPH)

U.S. Physical Therapy, Inc., Annual General Meeting, May 21, 2024

Is Now The Time To Look At Buying U.S. Physical Therapy, Inc. (NYSE:USPH)?

Executive VP recently sold US$213k worth of stock

Executive VP notifies of intention to sell stock

Price target increased by 9.0% to US$119

Chief Operating Officer - West recently sold US$274k worth of stock

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Shareholders Might Be Looking For Exit

Upcoming dividend of US$0.44 per share

Fourth quarter dividend increased to US$0.44

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

U.S. Physical Therapy, Inc. Increases Quarterly Dividend, Payable on April 5, 2024

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

The Returns On Capital At U.S. Physical Therapy (NYSE:USPH) Don't Inspire Confidence

Why U.S. Physical Therapy, Inc. (NYSE:USPH) Could Be Worth Watching

Now 20% undervalued after recent price drop

Price target decreased by 9.6% to US$110

Consensus EPS estimates fall by 10%

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 8, 2023

Price target decreased by 7.9% to US$118

Now 20% undervalued after recent price drop

U.S. Physical Therapy, Inc. to Report Q3, 2023 Results on Nov 07, 2023

U.S. Physical Therapy: Positioned For Market Dominance Amidst Attractive Valuations

Is U.S. Physical Therapy (NYSE:USPH) A Risky Investment?

U.S. Physical Therapy (NYSE:USPH) Could Be Struggling To Allocate Capital

Chief Operating Officer - West recently sold US$452k worth of stock

Should You Think About Buying U.S. Physical Therapy, Inc. (NYSE:USPH) Now?

Chief Operating Officer - West notifies of intention to sell stock

Second quarter 2023 earnings: EPS misses analyst expectations

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 8, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in U.S. Physical Therapy, Inc. (NYSE:USPH) for $2.1 million.

Are U.S. Physical Therapy, Inc. (NYSE:USPH) Investors Paying Above The Intrinsic Value?

U.S. Physical Therapy, Inc. to Report Q2, 2023 Results on Aug 08, 2023

U.S. Physical Therapy: Bolt-On Strategy Scaling Earnings Power (Rating Upgrade)

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 75% interest in Physical therapy practice with four clinics for $3.1 million

U.S. Physical Therapy, Inc. has completed a Follow-on Equity Offering in the amount of $150.00003 million.

Price target increased by 7.9% to US$119

U.S. Physical Therapy, Inc. Elects Nancy Ham to the Board of Directors

Upcoming dividend of US$0.43 per share at 1.6% yield

At US$114, Is U.S. Physical Therapy, Inc. (NYSE:USPH) Worth Looking At Closely?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

U.S. Physical Therapy Declares Quarterly Dividend, Payable on June 9, 2023

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Intrinsic Value Is Potentially 25% Below Its Share Price

U.S. Physical Therapy (NYSE:USPH) Has A Pretty Healthy Balance Sheet

Independent Director recently sold US$463k worth of stock

Executive VP recently sold US$92k worth of stock